Preliminary data from a phase I study evaluating the novel antibody-drug conjugate M9140 demonstrated encouraging activity in heavily pretreated patients with advanced colorectal cancer. The study was presented by principal investigator Scott Kopetz, professor of gastrointestinal medical oncology and associate vice president for Translational Integration at MD Anderson, at the 2024 American Society of Clinical Oncology Annual Meeting.
Preliminary data from the first-in-human phase I trial of RO7623066—a first-in-class inhibitor of ubiquitin-specific peptidase 1—show a promising safety profile as a single agent and signs of early anti-tumor activity for patients with advanced solid tumors. The data were presented by Timothy Yap, professor of investigational cancer therapeutics and vice president and head of clinical development in MD Anderson’s Therapeutics Discovery division, at the 2024 American Society of Clinical Oncology Annual Meeting.
Purple Biotech Ltd. announced positive interim data from its randomized, controlled, open label, multicenter phase II study of CM24 in second-line metastatic pancreatic ductal adenocarcinoma presented at a late-breaking abstract poster presentation at the 2024 American Society of Clinical Oncology Annual Meeting.
Researchers at UNC Lineberger Comprehensive Cancer Center and colleagues have established the most comprehensive molecular portrait of the workings of KRAS and how its activities impact pancreatic cancer outcomes.
FDA approved imetelstat (Rytelo, Geron Corporation), an oligonucleotide telomerase inhibitor, for adults with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia requiring four or more red blood cell units over eight weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents.
The National Cancer Institute approved the following clinical research studies last month.
Women make up more than half of the U.S. population and are well represented in medicine—but not so much in the top jobs in oncology.
While cutting-edge therapies grace headlines, the impact of breakthrough research remains limited due to patient access, affordability, and adherence.
Celebrating National Nurses Month means appreciating the vast roles, reach, and applications of nurses throughout the healthcare spectrum.
Dave Lew was named chief marketing officer at the American Cancer Society.
